SP
HCAT icon

Sarasin & Partners’s Health Catalyst HCAT Stock Holding History

Sarasin & Partners’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-48,482
Closed -$1.92M – 93
2021
Q4 		$1.92M Sell
48,482
-29,436
-38% -$1.34M 0.02% 89
2021
Q3 		$3.9M Buy
77,918
+16,835
+28% +$918K 0.04% 87
2021
Q2 		$3.39M Buy
61,083
+8,238
+16% +$439K 0.04% 96
2021
Q1 		$2.47M Hold
52,845
– – 0.03% 94
2020
Q4 		$2.3M Buy
+52,845
New +$1.95M 0.03% 98

Other funds holding HCAT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Sarasin & Partners's HCAT Position: Q1 2022 in Review

Sarasin & Partners sold out of Health Catalyst (HCAT) in Q1 2022, closing a stake of 48,482 shares — an estimated $1.92M sold.

Sarasin & Partners first reported a position in HCAT in Q4 2020 and held it in 5 quarters. The position peaked at $3.9M in Q3 2021. 185 funds tracked by Wall St. Rank hold HCAT as of Q1 2022.

  • Sarasin & Partners reported no remaining Health Catalyst position as of Q1 2022 after selling out during the quarter.
  • Sarasin & Partners sold 48,482 Health Catalyst shares in Q1 2022, an estimated $1.92M.
  • Sarasin & Partners first reported a position in Health Catalyst in Q4 2020 and held it in 5 quarters.
  • Sarasin & Partners's Health Catalyst position peaked at $3.9M in Q3 2021.
  • 185 funds tracked by Wall St. Rank held Health Catalyst as of Q1 2022.

Based on Sarasin & Partners's 13F filing for Q1 2022, filed 11 Apr 2022.